ES2534082T3 - Modulación terapéutica de la lubricación del límite del epitelio vaginal - Google Patents

Modulación terapéutica de la lubricación del límite del epitelio vaginal Download PDF

Info

Publication number
ES2534082T3
ES2534082T3 ES10732051.7T ES10732051T ES2534082T3 ES 2534082 T3 ES2534082 T3 ES 2534082T3 ES 10732051 T ES10732051 T ES 10732051T ES 2534082 T3 ES2534082 T3 ES 2534082T3
Authority
ES
Spain
Prior art keywords
prg4
protein
polynucleotide
vaginal
lubrication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10732051.7T
Other languages
English (en)
Spanish (es)
Inventor
Edward R. Truitt, Iii
Benjamin Sullivan
David Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Lubris LLC
Original Assignee
Schepens Eye Research Institute Inc
Lubris LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc, Lubris LLC filed Critical Schepens Eye Research Institute Inc
Application granted granted Critical
Publication of ES2534082T3 publication Critical patent/ES2534082T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
ES10732051.7T 2009-01-13 2010-01-13 Modulación terapéutica de la lubricación del límite del epitelio vaginal Active ES2534082T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14434409P 2009-01-13 2009-01-13
US144344P 2009-01-13
US26040209P 2009-11-12 2009-11-12
US260402P 2009-11-12
PCT/US2010/020929 WO2010083239A2 (en) 2009-01-13 2010-01-13 Therapeutic modulation of vaginal epithelium boundary lubrication

Publications (1)

Publication Number Publication Date
ES2534082T3 true ES2534082T3 (es) 2015-04-17

Family

ID=42340279

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10732051.7T Active ES2534082T3 (es) 2009-01-13 2010-01-13 Modulación terapéutica de la lubricación del límite del epitelio vaginal

Country Status (7)

Country Link
US (1) US8980840B2 (enExample)
EP (1) EP2381957B1 (enExample)
JP (2) JP2012515170A (enExample)
CN (1) CN102438645A (enExample)
CA (1) CA2749480C (enExample)
ES (1) ES2534082T3 (enExample)
WO (1) WO2010083239A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5449775B2 (ja) 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
EP2381957B1 (en) * 2009-01-13 2015-01-07 Lubris LLC Therapeutic modulation of vaginal epithelium boundary lubrication
CA3110817C (en) * 2009-05-22 2023-08-15 Lubris, Llc Application and uses of prg4 and therapeutic modulation thereof
US9107885B2 (en) * 2009-08-13 2015-08-18 Lubris Llc PRG4 treatment for interstitial cystitis
CN102552996A (zh) * 2010-12-07 2012-07-11 宁小静 人体润滑剂
ES2395801B1 (es) * 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP4062924A1 (en) 2013-11-26 2022-09-28 Lubris LLC Compositions and methods for inhibiting intercellular interactions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
EP3209301B1 (en) 2014-10-22 2023-06-07 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
RU2017129880A (ru) * 2015-01-26 2019-03-04 ЛУБРИС ЭлЭлСи Применение prg4 в качестве противовоспалительного средства
JP7291459B2 (ja) 2015-05-19 2023-06-15 ルブリス，エルエルシー． 動体視力および高次収差を改善するためのｐｒｇ４の使用
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3364978A4 (en) 2015-10-22 2019-06-05 Havah Therapeutics Pty Ltd METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3142193A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
WO2023042216A1 (en) * 2021-09-15 2023-03-23 Chemex Global Topical pharmaceutical compositions for treatment of infertility
CN118976097B (zh) * 2024-10-22 2025-01-24 北京岷德生物科技有限公司 一种治疗妇科疾病的组合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005A (en) * 1843-03-17 Power-loom
US7000A (en) * 1850-01-08 Smut-machine
US7027A (en) * 1850-01-15 Circulak
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
AU740758B2 (en) * 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US20030059489A1 (en) * 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
US7005408B2 (en) * 2002-05-01 2006-02-28 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US20060240037A1 (en) * 2003-06-04 2006-10-26 Edward Fey Methods and compositions for the treatment and prevention of degenerative joint disorders
UA91818C2 (ru) 2003-08-14 2010-09-10 Уайт Рекомбинантные молекулы лубрицина и их использование
EP1727802A1 (en) * 2004-02-25 2006-12-06 Smithkline Beecham Corporation Substituted quinoline compounds for use as selective estrogen receptor modulator
EP1740190A1 (de) * 2004-03-05 2007-01-10 Synthes GmbH Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelersatz in vitro
US8703198B2 (en) * 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
WO2007070067A1 (en) * 2005-12-16 2007-06-21 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
US20070264309A1 (en) * 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
WO2008143816A1 (en) * 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
GB0722507D0 (en) * 2007-11-19 2007-12-27 Zhao Xiaobin Hyaluronic acid personal lubricant
EP2381957B1 (en) * 2009-01-13 2015-01-07 Lubris LLC Therapeutic modulation of vaginal epithelium boundary lubrication

Also Published As

Publication number Publication date
CN102438645A (zh) 2012-05-02
CA2749480C (en) 2015-03-31
US8980840B2 (en) 2015-03-17
US20120052077A1 (en) 2012-03-01
CA2749480A1 (en) 2010-07-22
WO2010083239A3 (en) 2010-12-09
JP6039723B2 (ja) 2016-12-07
EP2381957A2 (en) 2011-11-02
WO2010083239A2 (en) 2010-07-22
EP2381957B1 (en) 2015-01-07
JP2012515170A (ja) 2012-07-05
JP2015180620A (ja) 2015-10-15
EP2381957A4 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
US12103955B2 (en) Polynucleotides encoding relaxin
US12274743B2 (en) Nucleic acid vaccines
CA2749480C (en) Therapeutic modulation of vaginal epithelium boundary lubrication
ES2532526T3 (es) Aplicación y usos de PRG4 y modulación terapéutica de la misma
ES2633792T3 (es) Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular
AU2023210606A1 (en) Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
US20200131498A1 (en) Polynucleotides encoding methylmalonyl-coa mutase
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2025271034A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
MXPA06010205A (es) Metodo y composiciones para el tratamiento de trastornos gastrointestinales.
US20200268666A1 (en) Polynucleotides encoding coagulation factor viii
US8822421B2 (en) E2F as a target of hormone refractory prostate cancer
JP7448219B2 (ja) Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物
ES2312442T3 (es) Variante alternativa de corte y empalme de glutamina fructosa-6-fosfato amidotransferasa y su producto de expresion.
TWI752110B (zh) 腦梗塞的治療藥
Yong et al. Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice
KR20070059009A (ko) 뮤신3 ｅｇｆ-유사 도메인
ES2288884T3 (es) Acido nucleico que codifica una proteina de la familia ctage, su uso y produccion.
WO2026082097A1 (zh) 多肽、rna分子及其医药用途
WO2000006727A2 (en) Human epidermal proteins hepi-1 to hepi-6
US20230348913A1 (en) Methods to re-engage a fetal wound healing pathway for adult skin repair
US20050048612A1 (en) Human epidermal proteins HEP1-1 to HEP1-6
AR045408A1 (es) Genes y polipeptidos relacionados con cancer de colon humano
ES2354811T3 (es) Factor inductor del factor nuclear kb.
JP5058980B2 (ja) 粘膜炎を処置するための増殖因子ａｍｐ−１８に由来するペプチドの使用